Vertaling van "for this product " (Nederlands → Frans) :

TERMINOLOGIE

product dat aescine bevat
produit contenant de l'aescine

product dat balsalazide bevat
produit contenant du balsalazide

product dat bacitracine bevat
produit contenant de la bacitracine

product dat barbituraat bevat
produit contenant du barbiturique

product dat basiliximab bevat
produit contenant du basiliximab

product dat baclofen bevat
produit contenant du baclofène

product dat auranofine bevat
produit contenant de l'auranofine

product dat auranofine in orale vorm bevat
produit contenant de l'auranofine sous forme orale

product dat enkel auranofine in orale vorm bevat
produit contenant seulement de l'auranofine sous forme orale

product dat baricitinib bevat
produit contenant du baricitinib

IN-CONTEXT TRANSLATIONS

As for D-glucuronolactone, the group believes that this concerns a normal human metabolite deriving from glucose, which does not involve a structural risk with regard to mutagenicity or carcinogenicity. It also holds that both this component as well as its hydrolysis product, glucuronic acid, are endogenous metabolites in humans and other mammals, that they are naturally present in various food sources and that they are quickly metabolised into innocuous products and excreted.
Pour la D-glucuronolactone, le groupe considère qu’il s’agit d’un métabolite humain normal provenant du glucose qui ne présente pas de risque structural en termes de mutagénicité ou de carcinogénicité, que pour ce composant, comme pour son produit d’hydrolyse, l’acide glucuronique, il s’agit de métabolites endogènes chez l’homme et les autres mammifères, qu’ils se trouvent à l’état naturel dans diverses sources alimentaires et qu’ils sont rapidement métabolisés en produits sans danger et excrétés.

Nevertheless, in view of the fact that this type of drink is already allowed in several European countries and taking into account the European regulations concerning this type of product, in the end, the competent French authorities have been obliged to give their approval (Decree of the European Court of Justice, Press release No. 12/04, 2004) for this beverage, which was marketed on 15 July 2008.
Néanmoins, considérant que ce type de boisson est déjà autorisé dans plusieurs pays d’européens et compte tenu de la réglementation européenne sur ce type de produit, les autorités compétentes françaises ont finalement dû l’autoriser (Arrêt de la Cour de Justice européenne, Communiqué de presse n° 12/04, 2004). Sa commercialisation a effectivement débuté en date du 15 juillet 2008.

The EU Tobacco Products Directive will be reviewed this year, and the Foundation could not miss this opportunity to bring this message to the EU decision-makers - www.cancer.be/plainpacks.
La directive européenne sur les produits du tabac doit être revue cette année ; la Fondation ne pouvait pas manquer cette occasion de répéter son message - www.cancer.be/plainpacks.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

This article stipulates The regulation states that production, quality and pharmacovigilance standards need to be determined for these products;
This article stipulates The regulation states that production, quality and pharmacovigilance standards need to be determined for these products;

As regards D- glucuronolactone, the SCF confirms its reservations about a daily chronic intake of 840 mg of the product (1.4 can) and an acute intake of 1 800 mg of the product (3 cans) via this type of drink, taking into account that the natural intake of D-glucuronolactone via food amounts to 1 to 2 mg/day (SCF, 2003).
Pour le D-glucuronolactone, le SCF confirme ses réserves dans le cadre d’un apport journalier chronique de 840 mg de produit (1,4 canette) et d’un apport aigu de 1.800 mg de produit (3 cannettes) via ce type de boisson et ce, tenant compte du fait que l’apport alimentaire naturel en D-glucuronolactone est de 1 à 2 mg/jour (SCF, 2003).

In December 2008 the Homeopathic and Herbal Medicinal Products Unit also published circular 533 regarding the notification of traditional herbal medicines. Finally, a specific database was developed for this.
In December 2008 the Homeopathic and Herbal Medicinal Products Unit also published circular 533 regarding the notification of traditional herbal medicines. Finally, a specific database was developed for this.

in healthy volunteers and patients. This entails investigating the safety and efficacy of increasing doses of the product and the pharmacokinetics in phase I and early phase II trials.
in healthy volunteers and patients. This entails investigating the safety and efficacy of increasing doses of the product and the pharmacokinetics in phase I and early phase II trials.

Each 250 ml bottle of this product contains the following ingredients (the following list is restricted to the ingredients that can cause problems in terms of food safety): 80 mg caffeine (or 320 mg/litre), 1 000 mg taurine (4 000 mg/litre), 600 mg glucuronolactone (2 400 mg/litre), 5 µg vitamin B12, 5 µg vitamin B6, 5 mg vitamin B5, 1.5 mg vitamin B2 and 20.5 mg vitamin B3.
Celle-ci contient, par flacon de 250 ml, les composants suivants (liste limitée aux substances pouvant poser problème en termes de sécurité alimentaire): 80 mg de caféine (soit 320 mg/litre), 1.000 mg de taurine (4.000 mg/litre), 600 mg de D-glucuronolactone (2.400 mg/litre), 5 µg de vitamine B12, 5 mg de vitamine B6, 5 mg de vitamine B5, 1,5 mg de vitamine B2 et 20,5 mg de vitamine B3.

It triggered a tremendous amount of positive reactions and led to a record number of visitors on the website. This radio spot was made by the working group Verder, in co-operation with individuals bereaved by suicide (including the actor Pol Goossen) and the production house La Vita e Media. It also had the support of the Flemish Minister of Well- Being, Public Health and Family.
Le spot radio a été réalisé par le groupe de travail Verder, en collaboration avec des proches (e.a. l’acteur Pol Goossen), la maison de production La Vita e Media et avec le soutien de la ministre flamande du Bien-être, de la Santé publique et de la Famille.